Roche and Regeneron are on the cusp of transforming the vascular endothelial growth factor A (VEGF-A) therapy market with their revolutionary treatments, Vabysmo and Eylea HD. These two groundbreaking drugs are forecast to capture over 60% of the market by 2030, setting a new standard in retinal disease therapies and challenging current industry leaders, according to GlobalData, a leading data and analytics company.

Vabysmo (faricimab), developed by Roche, was launched in 2022 with a unique bi-specific monoclonal antibody approach, targeting both VEGF-A and angiopoietin 2 (Ang-2). This dual mechanism significantly curtails cell division and angiogenesis, making it a vital treatment for neovascular (wet) age-related macular degeneration (wAMD) and diabetic macular edema (DME). The drug’s usability was extended further with its 2023 approval for treating retinal vein occlusion (RVO).

Eleni Tokali, Pharma Analyst at GlobalData, highlights: “Vabysmo’s innovative dual-action approach has rapidly propelled it to the forefront of retinal treatments. With sales soaring to $2.5 billion within a year of launch and projections hitting $7.7 billion by 2030, Vabysmo is a game-changer in the VEGF-A market.”

Eylea HD (aflibercept), Regeneron’s high-dose version of the original Eylea, has similarly made significant strides since its US approval in 2023. Eylea HD’s ability to bind all forms of VEGF-A and placental growth factor (PlGF) effectively halts the formation of new blood vessels. Its’ therapeutic application for wAMD, DME, and diabetic retinopathy (DR), reinforced by European approval in 2024, underscores its critical role in managing retinal diseases.

Tokali adds: “Eylea HD’s rapid market penetration and its compelling growth trajectory, with sales expected to skyrocket to $5.5 billion by 2030, reflect its pivotal role in reshaping treatment paradigms for retinal conditions. Its remarkable 65% CAGR is a testament to its efficacy and patient impact.”

According to GlobalData’s analysis, Vabysmo and Eylea HD are set to dominate the VEGF-A market, with combined sales reaching an estimated $13.3 billion by 2030. This commanding share reflects not only their clinical success but also a seismic shift in market dynamics. These two drugs are paving the way for new standards in retinal disease treatment, impacting both pricing strategies and future research and development directions.

Tokali concludes: “The anticipated performance of Vabysmo and Eylea HD represents a fundamental transformation in the treatment landscape for retinal diseases, with Roche and Regeneron leading this shift. As Vabysmo and Eylea HD continue their trajectory, their influence extends beyond immediate market success. They are setting new benchmarks for innovation and efficacy in retinal disease treatment, promising significant advancements in patient care and clinical outcomes.”